Actinium Pharmaceuticals (ATNM) Competitors

ALT5 Sigma (NASDAQ:ALTS) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Which has higher valuation & earnings, ALTS or ATNM?

ALT5 Sigma has higher revenue and earnings than Actinium Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$12.53M	9.45	-$6.24M	N/A	N/A
Actinium Pharmaceuticals	N/A	N/A	-$48.82M	-$1.31	-1.26

Is ALTS or ATNM more profitable?

Actinium Pharmaceuticals has a net margin of 0.00% compared to ALT5 Sigma's net margin of -74.89%. Actinium Pharmaceuticals' return on equity of -100.85% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-74.89%	-179.27%	-16.28%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Do insiders and institutionals hold more shares of ALTS or ATNM?

6.3% of ALT5 Sigma shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 4.9% of ALT5 Sigma shares are owned by insiders. Comparatively, 6.0% of Actinium Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Do analysts prefer ALTS or ATNM?

Actinium Pharmaceuticals has a consensus target price of $4.50, indicating a potential upside of 172.73%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to ALTS or ATNM?

In the previous week, ALT5 Sigma had 12 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 17 mentions for ALT5 Sigma and 5 mentions for Actinium Pharmaceuticals. Actinium Pharmaceuticals' average media sentiment score of 1.03 beat ALT5 Sigma's score of 0.54 indicating that Actinium Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALT5 Sigma	4 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Actinium Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, ALTS or ATNM?

ALT5 Sigma has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of -0.53, meaning that its share price is 153% less volatile than the S&P 500.

Summary

Actinium Pharmaceuticals beats ALT5 Sigma on 8 of the 13 factors compared between the two stocks.